Polymeric enhancers of mucosal epithelia permeability: Synthesis, transepithelial penetration-enhancing properties, mechanism of action, safety issues

被引:81
作者
Di Colo, Giacomo [1 ]
Zambito, Ylenia [1 ]
Zaino, Chiara [1 ]
机构
[1] Univ Pisa, Dept Bioorgan Chem & Bippharmaceut, I-56126 Pisa, Italy
关键词
transmucosal drug delivery; absorption enhancer; permeation enhancer; polymeric biomaterials; polymer synthesis; chitosan; paracellular transport; transcellular transport; tight junction; toxicity;
D O I
10.1002/jps.21043
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Transmucosal drug administration across nasal, buccal, and ocular mucosae is noninvasive, eliminates hepatic first-pass metabolism and harsh environmental conditions, allows rapid onset, and further, mucosal surfaces are readily accessible. Generally, however, hydrophilic drugs, such as peptides and proteins, are poorly permeable across the epithelium, which results in insufficient bioavailability. Therefore, reversible modifications of epithelial barrier structure by permeation enhancers are required. Low molecular weight enhancers generally have physicochemical characteristics favoring their own absorption, whereas polymeric enhancers are not absorbed, and this minimizes the risk of systemic toxicity. The above considerations have warranted the present survey of the studies on polymeric transmucosal penetration-enhancers that have appeared in the literature during the last decade. Studies on intestinal permeation enhancers are also reviewed as they give information on the mechanism of action and safety of polymers. The synthesis and characterization of polymers, their effectiveness in enhancing the absorption of different drugs across different epithelium types, their mechanism of action and structure-efficacy relationship, and the relevant safety issues are reviewed. The active polymers are classified into: polycations (chitosan and its quaternary ammonium derivatives, poly-L-arginine (poly-L-Arg), aminated gelatin), polyanions (N-carboxymethyl chitosan, poly(acrylic acid)), and thiolated polymers (carboxymethyl cellulose-cysteine, polycarbophil (PCP)-cysteine, chitosan-thiobutylamidine, chitosan-thioglycolic acid, chitosan-glutathione conjugates). (c) 2007 Wiley-Liss, Inc. and the American Pharmacists Association.
引用
收藏
页码:1652 / 1680
页数:29
相关论文
共 128 条
[1]   HYDROGEN-ION TITRATION OF CHITOSANS WITH VARYING DEGREES OF N-ACETYLATION BY MONITORING INDUCED H-1-NMR CHEMICAL-SHIFTS [J].
ANTHONSEN, MW ;
SMIDSROD, O .
CARBOHYDRATE POLYMERS, 1995, 26 (04) :303-305
[2]   EFFECT OF CHITOSAN ON THE PERMEABILITY OF MONOLAYERS OF INTESTINAL EPITHELIAL-CELLS (CACO-2) [J].
ARTURSSON, P ;
LINDMARK, T ;
DAVIS, SS ;
ILLUM, L .
PHARMACEUTICAL RESEARCH, 1994, 11 (09) :1358-1361
[3]   Chitosan as a nasal delivery system: The effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers [J].
Aspden, TJ ;
Mason, JDT ;
Jones, NS ;
Lowe, J ;
Skaugrud, O ;
Illum, L .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (04) :509-513
[4]   CHARACTERIZATION OF CHITOSANS VIA COUPLED SIZE-EXCLUSION CHROMATOGRAPHY AND MULTIPLE-ANGLE LASER LIGHT-SCATTERING TECHNIQUE [J].
BERI, RG ;
WALKER, J ;
REESE, ET ;
ROLLINGS, JE .
CARBOHYDRATE RESEARCH, 1993, 238 :11-26
[5]   In vitro evaluation of the potential of thiomers for the nasal administration of Leu-enkephalin [J].
Bernkop-Schnuerch, A. ;
Obermair, K. ;
Greimel, A. ;
Palmberger, T. F. .
AMINO ACIDS, 2006, 30 (04) :417-423
[6]   Thiolated chitosans:: development and in vitro evaluation of a mucoadhesive, permeation enhancing oral drug delivery system [J].
Bernkop-Schnürch, A ;
Guggi, D ;
Pinter, Y .
JOURNAL OF CONTROLLED RELEASE, 2004, 94 (01) :177-186
[7]   Thiolated polymers-thiomers:: synthesis and in vitro evaluation of chitosan-2-iminothiolane conjugates [J].
Bernkop-Schnürch, A ;
Hornof, M ;
Zoidl, T .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 260 (02) :229-237
[8]   Advances in buccal drug delivery [J].
Birudaraj, R ;
Mahalingam, R ;
Li, XL ;
Jasti, BR .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2005, 22 (03) :295-330
[9]  
Bodek K. H., 1995, ACTA POL PHARM, V52, P337
[10]  
Cano-Cebrian Maria Jose, 2005, Current Drug Delivery, V2, P9, DOI 10.2174/1567201052772834